Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (NCT06430684)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: 1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? 2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests? Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care. Study Procedures Include * For participants randomly selected for treatment, take empagliflozin once daily for 3 months * Phone calls with researchers every 2 weeks for check-ins * For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests * All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests
Who can join: Review the eligibility criteria below.
Location: Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Age range: 12 Years to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 227-6160
Email: alexkula@luriechildrens.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Diseases
- Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease — Port Jefferson Station, New York
- Combination of Novel Therapies for CKD Comorbid Depression — Stony Brook, New York
- Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) — Winnipeg, Manitoba
- Developing Tools for Dialysis Decision Support — Palo Alto, California
- BRINK (BRain In Kidney Disease) Memory Study 2.0 — Minneapolis, Minnesota
- Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Chicago, Illinois
Explore by condition: All Chronic Kidney Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.